secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001193125-22-251264
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences CMO Michael Panzara resigns; Anne-Marie Li-Kwai-Cheung promoted to CDO
--------------------------------------------------------------------------------

- Michael Panzara, M.D., MPH, resigns as CMO effective Oct 14, 2022, to pursue another opportunity; no disagreement with company.
- Dr. Panzara will serve as consultant post-resignation for transition.
- Anne-Marie Li-Kwai-Cheung promoted to Chief Development Officer effective Oct 14, 2022.
- Li-Kwai-Cheung previously led Roche's tominersen Phase 3 program and Ocrevus global launch.
- She brings deep neurology and rare disease drug development experience to Wave.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/d392497d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-251264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer